Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02744755 · ClinicalTrials.gov registry record · Phase 3
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Phase 3 study, sponsored by Sandoz.
- Completed
- Registry status
- Phase 3
- Development phase
- 353
- Enrollment target
NCT02744755 is a Phase 3 study that has completed, run by Sandoz. The registered enrollment target is 353 participants.
The verdict
NCT02744755, a Phase 3 study, has completed, sponsored by Sandoz.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 353 participants
- Enrollment target
Study Summary
Clinical trial to compare treatment with GP2017 and Humira® in patients with Rheumatoid Arthritis
Interventions
- BIOLOGICAL Adalimumab - GP2017
- BIOLOGICAL Adalimumab - US licensed Humira
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 353 participants |
| Start Date | 2016-03-31 |
| Est. Completion | 2017-09-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02744755
The ClinicalTrials.gov registry entry for NCT02744755 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 353 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sandoz, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Adalimumab - GP2017 is the first listed.
NCT02744755 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02744755 about?
NCT02744755 is a clinical study titled "Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis". Clinical trial to compare treatment with GP2017 and Humira® in patients with Rheumatoid Arthritis
What is the current status of trial NCT02744755?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 353 participants. The study started on 2016-03-31. Estimated completion is 2017-09-26.
What interventions are being tested in trial NCT02744755?
The interventions under investigation include: Adalimumab - GP2017 (BIOLOGICAL), Adalimumab - US licensed Humira (BIOLOGICAL).
Who is sponsoring clinical trial NCT02744755?
This trial is sponsored by Sandoz, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.